The Claim

In adults with MASLD without type 2 diabetes, 12 weeks of liraglutide therapy improves glucose tolerance and reduces HbA1c more than matched lifestyle-induced weight loss, and these improvements fully reverse within 12 weeks after discontinuation of liraglutide.

Source: Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
68score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with MASLD but without type 2 diabetes, 12 weeks of liraglutide treatment leads to greater improvements in glucose tolerance and lower HbA1c levels compared to weight loss from lifestyle changes, but these improvements disappear completely 12 weeks after stopping the drug.

See the scientific wording

In adults with MASLD without type 2 diabetes, 12 weeks of liraglutide therapy improves glucose tolerance and reduces HbA1c more than matched lifestyle-induced weight loss, but these benefits fully reverse within 12 weeks after discontinuation, suggesting transient pharmacological effects on glucose metabolism.

Why this might work

Liraglutide binds to receptors on pancreatic cells, causing them to release more insulin when blood sugar rises. This insulin helps fat tissue absorb more glucose from the blood, lowering overall sugar levels and reducing the raw material available for the liver to make fat. When the drug stops, fat tissue becomes inflamed and releases signals that disrupt insulin response, while gut bacteria shift toward a profile that promotes fat storage, causing blood sugar to rise again.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

    In people with fatty liver but no diabetes, liraglutide helped control blood sugar better than dieting alone—but when they stopped taking the drug, their blood sugar went back to how it was before, showing the benefit was only while taking the medicine.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.